Table 1

Relation of commercially available therapeutic agents and new molecular subtypes6

DLBCL molecular subtypePotential therapeutic agent
MCD/C5Ibrutinib, acalabrutinib, venetoclax
BN2/C1Ibrutinib, bortezomib, carfilzomib
EZB/C3Venetoclax, idelalisib, copanlisib, duvelisib
C4Idelalisib, copanlisib, duvelisib, bortezomib, carfilzomib, ruxolitinib
  • DLBCL, diffuse large B-cell lymphoma.